CONTACT US   |  (864) 397-5101

SCbio Member GRAIL Named to TIME’s List of the Best Inventions of 2022

Galleri featured in TIME

Today, TIME revealed its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives.

We are honored to have GRAIL’s Galleri® test named among the top inventions of 2022. The Galleri test is a multi-cancer early detection (MCED) test that can detect a shared cancer signal across more than 50 types of cancer1 through a simple blood draw.

Using next-generation genomic sequencing and machine-learning technologies, the Galleri test detects a signal associated with cancer and includes one or two predictions of where in the body the cancer signal originated.

“I am thrilled to see the Galleri test included in TIME’s list of best inventions of 2022,” said Bob Ragusa, chief executive officer at GRAIL. “We believe strongly in the importance of early cancer detection and the impact it can make on patients’ lives. This test is a promising new tool in our fight against cancer.”

To compile the list, TIME solicited nominations from TIME’s editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as the electric vehicle industry, medical care, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.

Of the new list, TIME’s editors write: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including life-mapping artificial intelligence, diamonds made from excess carbon in the air, and the most powerful telescope ever—that are changing how we live, work, play, and think about what’s possible.”

See the full list here: time.com/best-inventions-2022

1 Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation n-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177.

###

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021.

For more information, visit grail.com.
 

About Galleri®

The earlier that cancer is detected, the higher the chance of successful outcomes. The Galleri multi-cancer early detection test can detect signals across more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is detected, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, with high accuracy to help guide the next steps to diagnosis. The Galleri test is available in the U.S. and requires a prescription from a licensed healthcare provider. The Galleri test should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or older.

All cells—cancer and healthy ones—shed DNA, which is called cell-free DNA, into the bloodstream. One of the “hallmarks of cancer” is when methyl groups are added to DNA. This does not alter the DNA code but it can alter gene expression. Methylation patterns on tumor-derived cell-free DNA carry cancer-specific signals and are therefore very helpful in detecting cancer and determining its origin. Galleri uses next-generation sequencing and machine learning algorithms to analyze these methylation patterns of cell-free DNA in the bloodstream.

For more information about Galleri, visit galleri.com.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.